iPro® Professional CGMS System
The easy way to reveal glycaemic patterns
Fingersticks only give part of the picture10
Fingersticks only give part of the picture
Discover patterns and problems that HbA1C testing, logbooks, and blood glucose (BG) meters cannot uncover alone by filling the gaps with Continuous Glucose Monitoring.

The new CGMS iPro® is is a technological leap forward in blind CGM for Healthcare Professionals. Use simple evaluation to gain critical insights into glycaemic patterns.


Healthcare Professionals prescribe Continuous Glucose Monitoring (CGM) for their diabetes patients because the trend data can give them a clearer picture of blood glucose levels throughout the day and night. The Medtronic sensor provides an average blood sugar measurement every 5 minutes, for 3 days at a time. That's 288 readings a day! So when your healthcare professional downloads the data collected, you have an increased depth of information for you and your healthcare team to make clinical decisions.

 

iPro - The NEW Professional CGM System
The CGMS iPro® system really is an innovation in blind CGM.
  • Small & discreet
  • Waterproof
  • No cables or monitor necessary
  • No patient interaction required


 

Easy to Use
IPRO

The iPro® Professional CGMS uses the same Medtronic glucose sensor as the Guardian REAL-Time®11 and the MiniMed Paradigm® VEO12 CGM products, so its use and insertion are familiar to you and your patients, and can also make your own inventory management easier.

3 Easy Steps

1. Patient visits the Clinic. The patient is set up in the software, glucose sensor inserted and the iPro® connected.
2. At home. All the patient needs to do is record 4 of their regular Fingerstick readings per day. The iPro® holds onto the glucose sensor data until the end of the test period.
3. Patient's second visit to the Clinic . The glucose sensor data is downloaded for the software to provide comprehensive glycaemic trend data and easy to read reports.

Clinical References
  1. skyler Js. The economic burden of diabetes and the benefits of improved glycemic control: the potential role of a continuous glucose monitoring system. Diabetes Technol Ther. 2000;2(suppl 1):s7-s12.
  2. Derr r, Garrett e, stacy Ga, saudek CD. is Hba(1c) affected by glycemic instability? Diabetes Care. 2003;26(10):2728-2733.
  3. The Diabetes Control and Complications Trial research Group. Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes. 1997;46(2):271-286.
  4. Gross TM, Mastrototaro JJ. efficacy and reliability of the continuous glucose monitoring system. Diabetes Technol Ther. 2000;2(suppl 1):s19-s26.
  5. Gross TM, Bode BW, einhorn D, et al. Performance evaluation of the MiniMed continuous glucose monitoring system during patient home use. Diabetes Technol Ther. 2000;2(1):49-56.
  6. Kaufman fr, Gibson lC, Halvorson M, Carpenter s, fisher lK, Pitukcheewanont P. a pilot study of the continuous glucose monitoring system: clinical decisions and glycemic control after its use in pediatric type 1 diabetic subjects. Diabetes Care. 2001;24(12):2030-2034.
  7. Bode BW, Gross TM, Thornton Kr, Mastrototaro JJ. Continuous glucose monitoring used to adjust diabetes therapy improves glycosylated hemoglobin: a pilot study. Diabetes Res Clin Pract. 1999;46(3):183-190.
  8. Tanenberg r, Bode B, lane W, et al. Use of the Continuous Glucose Monitoring system to guide therapy in patients with insulin-treated diabetes: a randomized controlled trial. Mayo Clin Proc. 2004;79(12):1521-1526.
  9. ludvigsson J, Hanas r. Continuous subcutaneous glucose monitoring improved metabolic control in pediatric patients with type 1 diabetes: a controlled crossover study. Pediatrics. 2003;111(5 pt 1):933-938
  10. scheiner G, Boyer Ba. Characteristics of basal insulin requirements by age and gender in Type-1 diabetes patients using insulin pump therapy. Diabetes Res Clin Pract. 2005;69(1):14-21.
  11. Pitzer Kr, Desai s, Dunn T, et al. Detection of hypoglycemia with the GlucoWatch biographer. Diabetes Care. 2001;24(5):881-885.